Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 20/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 3/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6903749 | 1.00 | ESR1 (1.00) | ESR1ESR2PGR | |
| SCHEMBL407674 | 1.00 | ESR1 (1.00) | ESR1ESR2PGR | |
| SCHEMBL667262 | 1.00 | ESR1 (1.00) | ESR1ESR2PGR | |
| SCHEMBL5070367 | 0.94 | ESR1 (1.00) | ESR1ESR2PGR | |
| SCHEMBL28483063 | 0.94 | ESR1 (1.00) | ESR1ESR2PGR | |
| SCHEMBL5070366 | 0.94 | ESR1 (1.00) | ESR1ESR2PGR | |
| SCHEMBL21512474 | 0.94 | ESR1 (1.00) | ESR1ESR2PGR | |
| SCHEMBL5070365 | 0.94 | ESR1 (1.00) | ESR1ESR2PGR | |
| SCHEMBL1881237 | 0.93 | ESR1 (0.87) | ESR1ESR2PGR | |
| SCHEMBL1881240 | 0.93 | ESR1 (0.87) | ESR1ESR2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113750091-B | Methods for treating cancer | 雷迪厄斯制药公司 | 2025-03-11 | — | — | CN | disclosed |
| US-20230310385-A1 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI-ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-10-05 | — | — | US | disclosed |
| EP-3373967-B9 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-10-04 | — | — | EP | disclosed |
| CN-108348605-B | Treatment of ER-negative breast cancer with PDGF-CC inhibitors and antiestrogens | 帕拉卡林治疗公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-3373967-B1 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-06-07 | — | — | EP | disclosed |
| US-11633382-B2 | Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen | PARACRINE THERAPEUTICS AB (SE) | 2023-04-25 | — | — | US | disclosed |
| EP-4039253-A1 | METHODS OF TREATING CANCER | Radius Pharmaceuticals, Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| CN-113750091-A | Methods for treating cancer | 雷迪厄斯制药公司 | 2021-12-07 | — | — | CN | disclosed |
| CN-108024540-B | Methods for treating cancer | 雷迪厄斯制药公司 | 2021-09-17 | — | — | CN | disclosed |
| CN-113288887-A | Methods for treating cancer | 雷迪厄斯制药公司 | 2021-08-24 | — | — | CN | disclosed |
| EP-2826475-A1 | Trans-clomiphene for treating diabetes in hypogonadal men | Repros Therapeutics Inc. (US) | 2015-01-21 | — | — | EP | disclosed |
| WO-2014008159-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS FOR TREATMENT OF TAMOXIFEN RESISTANT TUMORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2014-01-09 | — | — | WO | disclosed |
| US-20130165524-A1 | TRANS-CLOMIPHENE FOR METABOLIC SYNDROME | REPROS THERAPEUTICS INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8377991-B2 | Trans-clomiphene for metabolic syndrome | REPROS THERAPEUTICS INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8372887-B2 | Trans-clomiphene for metabolic syndrome | REPROS THERAPEUTICS INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120022167-A1 | Trans-Clomiphene for Metabolic Syndrome | REPROS THERAPEUTICS INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-7737185-B2 | treating wasting in a hypogonadal male with chronic obstructive pulmonary disorder, especially a loss of muscle mass; reducing side effects while elevating serum testosterone levels | REPROS THERAPEUTICS INC. (US) | 2010-06-15 | — | — | US | disclosed |
| WO-2010054248-A1 | TRANS-CLOMIPHENE FOR METABOLIC SYNDROME AND DIABETES MELLITUS TYPE 2 | REPROS THERAPEUTICS INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| US-20090099265-A1 | TRANS-CLOMIPHENE FOR METABOLIC SYNDROME | REPROS THERAPEUTICS INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20070249726-A1 | treating wasting in a hypogonadal male with chronic obstructive pulmonary disorder, especially a loss of muscle mass; reducing side effects while elevating serum testosterone levels | REPROS THERAPEUTICS INC. | 2007-10-25 | — | — | US | disclosed |